The world is finally getting to grips with the consequences of drug prices.
As more than $1 trillion in new drug prices is being imposed on pharmaceutical companies, researchers and politicians have been looking to assess the impact.
Here’s what you need to know.
article The price of a drug is set by a variety of factors, such as its drug class, type, brand and dosage.
The latest US Drug Enforcement Agency (DEA) figures show that a single drug, Zyrtec, sold for $16.99 in 2012, was $3,636 in 2016, and $2,724 in 2020.
The cheapest generic, Zohydro, was sold for just $3.50.
That’s more than double the price of generic medicines sold in Europe.
Meanwhile, generic versions of two new medicines, Prozac and Zyprexa, are being made for as little as $10 each.
In the US, generics of those drugs, and the newer generics, are not yet on the market.
The price for Zypreya was cut by 75% in 2018, to $12.95 per pill.
But it’s still cheaper than the old generic version.
That is because the new generic version contains less of the drug, making it more affordable.
The most expensive drug on the planet is a brand-name brand of antipsychotic drugs, known as Risperdal, which cost $1,100 per month in 2016.
That costs more than three times as much as generic versions available in Europe, including Pfizer’s Paxil.
Other drugs that are cheaper than Risporadl are Trazodone and Imipramine, both of which cost about $1 per day.
For the drugs used to treat schizophrenia, the price difference is even greater.
Risparadise cost $17.15 per month for its original version, but the price dropped to $10.60 in 2017.
And its new generic cost $8.60 a month, with no changes in the price since then.
The new generic versions were also less expensive than the older ones.
So far, prices have been falling rapidly.
In 2017, a single generic version of the antipsychotics Risprod and Zyrtesic was sold at $18.60 per month.
That was down from $27.40 in 2018.
In 2019, the generic version sold for as low as $6.80 a month.
The US Department of Health and Human Services (HHS) estimates that there will be $2.5 trillion in annual price increases by 2020, with prices in the US rising to $6,878 per capita by 2020.
Prices of prescription drugs in Europe have been steadily dropping since 2006.
In 2014, prices for the same drugs were down by about a third.
But since then, they have risen by about two-thirds.
And by 2020 the drugs will be nearly three-quarters cheaper than they were a decade ago.
The rise in prices is largely driven by the emergence of generic versions.
The cheaper versions are used in some countries, but not in others.
For example, generically produced Paxil costs $3 more per pill in Canada than the original version.
And generically made Imiprapam is more expensive than it was in Canada.
But that has less to do with generics than with the way the drugs are made.
When a drug’s manufacturer uses a different type of drug than the ones in a generic version, the manufacturer can save money by producing less of it, said David Eakin, an associate professor of medicine at the Johns Hopkins University School of Medicine.
In some countries the cost of the drugs has been so low that they are cheaper in Europe than in the United States.
The cost of generic version Imiprime in Canada has fallen by $2 in the last decade, from $12 to $7.
This has reduced the demand for Imipril in Canada, and made Imiphos in the U.S. cheaper.
“It’s been a very strong seller in Europe and the United Kingdom and other countries,” said Eakin.
But in the same period, generic version Rispraglin was up by more than two-and-a-half times, from about $6 to $18 per month, and generic version Trazlodone is up by over half, from less than $10 to more than four-and.ends-and-$10 a month in the UK.
The generic versions have also been cheaper in China, where prices for RisPraglin and Imiphlops were $1 and $4, respectively.
And the cost in Europe is not as dramatic.
Generic versions of Riseprime and ImiPrip are now cheaper than in Canada and the U, and Imimax, the cheaper version of Imiprip, is $3 cheaper than it is in Canada for both the drug and the generic